[go: up one dir, main page]

ECSP10010446A - Uso de ranolazina para el tratamiento del dolor - Google Patents

Uso de ranolazina para el tratamiento del dolor

Info

Publication number
ECSP10010446A
ECSP10010446A EC2010010446A ECSP10010446A ECSP10010446A EC SP10010446 A ECSP10010446 A EC SP10010446A EC 2010010446 A EC2010010446 A EC 2010010446A EC SP10010446 A ECSP10010446 A EC SP10010446A EC SP10010446 A ECSP10010446 A EC SP10010446A
Authority
EC
Ecuador
Prior art keywords
ranolazine
pain
treatment
patient
visceral
Prior art date
Application number
EC2010010446A
Other languages
English (en)
Inventor
Ivan Diamond
Luiz Belardinelli
John Shryock
Sridharan Rajamani
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Publication of ECSP10010446A publication Critical patent/ECSP10010446A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se relaciona con métodos para tratar un paciente que sufre de dolor neuropático o nociceptivo que puede ser de naturaleza mecánica, visceral y/o inflamatoria, que comprende administrar una cantidad terapéuticamente efectiva de Ranolazina a un paciente necesitado de la misma.
EC2010010446A 2008-02-06 2010-09-03 Uso de ranolazina para el tratamiento del dolor ECSP10010446A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2669908P 2008-02-06 2008-02-06
US5743708P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
ECSP10010446A true ECSP10010446A (es) 2010-10-30

Family

ID=40548472

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010446A ECSP10010446A (es) 2008-02-06 2010-09-03 Uso de ranolazina para el tratamiento del dolor

Country Status (13)

Country Link
US (1) US20090203707A1 (es)
EP (1) EP2252294A1 (es)
KR (1) KR20110013348A (es)
CN (1) CN101977605A (es)
AU (1) AU2009212254A1 (es)
BR (1) BRPI0908428A2 (es)
CA (1) CA2713521A1 (es)
CO (1) CO6290663A2 (es)
EA (1) EA201070914A1 (es)
EC (1) ECSP10010446A (es)
IL (1) IL207292A0 (es)
MA (1) MA32132B1 (es)
WO (1) WO2009100380A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332540A1 (en) 2002-05-21 2011-06-15 Cv Therapeutics, Inc. Administration of ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2429526A1 (en) * 2009-05-14 2012-03-21 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
SMT201700456T1 (it) 2009-07-27 2017-11-15 Gilead Sciences Inc Composti eterociclici fusi come modulatori dei canali ionici
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
PL2707361T3 (pl) 2011-05-10 2018-01-31 Gilead Sciences Inc Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
SG11201604457XA (en) 2013-12-19 2016-07-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
WO2017152062A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
FI3548033T3 (fi) 2016-11-28 2024-07-10 Praxis Prec Medicines Inc Yhdisteitä ja menetelmiä niiden käyttämiseksi
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019232209A1 (en) 2018-05-30 2019-12-05 Praxis Precision Medicines, Inc. Ion channel modulators
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
MX2022006452A (es) 2019-11-27 2022-07-11 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657264A (en) * 1985-11-01 1987-04-14 Ingersoll-Rand Company Fluid seal assembly with segmented sub-assembly
DE69033967T2 (de) * 1989-06-23 2002-12-19 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
EP2033633A3 (en) * 2000-02-18 2009-07-08 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP2332540A1 (en) * 2002-05-21 2011-06-15 Cv Therapeutics, Inc. Administration of ranolazine for the treatment of diabetes
CN101098682A (zh) * 2005-01-06 2008-01-02 Cv医药有限公司 包括雷诺嗪的缓释药物制剂
JP2009516751A (ja) * 2005-11-21 2009-04-23 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティー・オブ・アラバマ・フォー・アンド・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アラバマ 神経保護のための小分子化合物を使用する方法
CA2653056A1 (en) * 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
CA2682207A1 (en) * 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors
CA2681444A1 (en) * 2007-04-12 2008-10-23 Cv Therapeutics, Inc. Ranolazine for enhancing insulin secretion
CN101917987A (zh) * 2007-11-06 2010-12-15 吉利德帕洛阿尔托股份有限公司 治疗精神病障碍的aldh-2抑制剂

Also Published As

Publication number Publication date
CO6290663A2 (es) 2011-06-20
CN101977605A (zh) 2011-02-16
EA201070914A1 (ru) 2011-04-29
KR20110013348A (ko) 2011-02-09
EP2252294A1 (en) 2010-11-24
BRPI0908428A2 (pt) 2015-12-08
MA32132B1 (fr) 2011-03-01
US20090203707A1 (en) 2009-08-13
AU2009212254A1 (en) 2009-08-13
WO2009100380A1 (en) 2009-08-13
CA2713521A1 (en) 2009-08-13
IL207292A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
ECSP10010446A (es) Uso de ranolazina para el tratamiento del dolor
CY1124103T1 (el) Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
HN2012000297A (es) Composicion para tratar la fibrosis quistica
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
CR20110560A (es) Métodos de tratamiento para tumores sólidos
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
ECSP11011459A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
PH12012500916B1 (en) Treatments for gastrointestinal disorders
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201001865A1 (ru) Противовоспалительные агенты
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
CY1117184T1 (el) ΤΕΛΕΣΤΕΣ β-ΑΡΡΕΣΤΙΝΗΣ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΚΑΙ ΜΕΘΟΔΟΙΧΡΗΣΗΣ ΑΥΤΩΝ
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
EA201200428A1 (ru) Композиция и способ для лечения ожирения
UY30915A1 (es) Método de tratamiento de canceres